Most patients in the cohort experienced symptomatic severe neutropenia requiring antibiotics and G-CSF, and nearly a 20% recurrence rate was observed in patients continuing anti-CD20 therapy (Rossi et al., 2022). Here, MS4A1 is linked to neutropenia.